UNSPSC 51352203: Chlorotrianisene

This classification denotes a non-steroidal estrogen with the molecular formula C23H21ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6V5034L121, chemically known as 1,1,1-(1-chloro-1-ethenyl-2-ylidene)-tris(4-methoxybenzene) but generally known as chlorotrianisene, which bears US NIH Compound Identifier 11289. European Medicines Agency schedules Chlorotrianisene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06199MIG.

UNSPSC 51352203 Chlorotrianisene is a Commodity code for a specific pharmaceutical ingredient, but state and local procurement activity under this code involves broader generic multi-source pharmaceutical and over-the-counter product supply agreements rather than chlorotrianisene in isolation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body soliciting under this code's scope, establishing master contracts for participating state and local government facilities to procure listed pharmaceutical products through authorized wholesalers. Vendors responding to MMCAP solicitations must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), hold contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), and provide comprehensive product information including NDC codes, strength, dosage form, and manufacturing location for each offering.

The code shows recent activity centered in Minnesota and Oregon through the MMCAP cooperative purchasing vehicle. The Minnesota Department of Administration issued an RFP (Solicitation S1070000015802) in January 2026 with a March 26, 2026 response date to establish multiple pharmaceutical supplier contracts effective July 1, 2026, with a two-year initial term and optional extensions. Evaluation heavily weights price competitiveness (75 percent) with additional credits for fixed pricing, administrative fee compliance, EDI capability, and the vendor's agreement to a 3 percent administrative fee on all purchases. Vendors must carry commercial general liability insurance of at least $5 million per occurrence and accept performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. The source does not identify specific award dollar values, set-aside designations, or restrictions by business classification.